Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
10 in stock (can be backordered) Tirzepatide is a dual GIP/GLP-1 receptor agonist (twincretin) developed by Eli Lilly and approved by the FDA in 2022 for type 2 diabetes (Mounjaro) and in 2023 for obesity (Zepbound)
In fact, Dr Anthony Fauci, the Director of the National Institute for Allergy and Infectious Diseases, reported that patients who had COVID-19 often develop a post-viral syndrome that is remarkably like Chronic Fatigue Syndrome [4]
However, if the supply of ketones such as lactate is inadequate, glia cells can break down the myelin sheath of axons in white matter sections of the brain, which is made of lipids, to produce ketones
Accessed June 9, 2026.
